Compare Neurocrine Biosciences Inc (NBIX) vs Rockwell Automation (ROK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Rockwell Automation — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Rockwell Automation trades at $466.2 (market cap $51.04B). The key difference: Rockwell Automation is far larger — about 2.9× Neurocrine Biosciences Inc's market cap, and Rockwell Automation pays a 1.2% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | ROK | |
|---|---|---|
Market Cap | $17.40B | $51.04B |
Sector | Health | Industrials |
52-Week High | $180.55 | $495.08 |
52-Week Low | $123.10 | $328.67 |
Enterprise Value | $16.49B | $54.67B |
Dividend Yield | — | 1.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $173.00, up 1.24% today, with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with Q1 2026 EPS of $1.94 beating expectations by 59%, revenue growth to $3.1B in 2026, and net income margin expanding to 21.55%. Recent news highlights executive appointments and positive clinical trial updates for crinecerfont, supporting growth prospects.
Outlook remains positive with 86% analyst buy ratings and a $196.08 consensus price target implying 13% upside. Key risks include execution of pipeline developments and integration of acquisitions. The stock's valuation at P/E 26.62 appears reasonable given earnings growth trajectory and strong profitability metrics.
Rockwell Automation (ROK) trades at $464.82, up 0.64% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 48.92% gross margin and 12.45% net margin, though valuation multiples like a 47.63 P/E appear elevated. Recent news highlights growth in industrial automation and AI infrastructure partnerships, including a contract with Aalo Atomics for nuclear reactor control systems (PRNewsWire, July 16, 2026).
Outlook is mixed: analyst consensus is a Buy with a $471.71 price target, but technical indicators suggest near-term pressure. Risks include margin compression and high debt levels, while opportunities lie in automation demand and new contracts. The stock offers a dividend yield of approximately 0.6% with consistent payouts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Rockwell Automation
Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →
